Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer.
John JiangHans-Peter AdamsMaria LangeSandra SiemannMirjam FeldkampSylvie McNamaraSebastian FroehlerStephanie J YaungLijing YaoAarthi BalasubramanyamNalin TikooChristine JuH Jost AchenbachRainer KrügelJohn F PalmaPublished in: BMC cancer (2020)
Longitudinal monitoring of mutational changes in plasma has the potential to predict disease progression early. The presence of ctDNA mutations during first-line treatment is a risk factor for earlier disease progression in advanced NSCLC.